Susan J. Schniepp - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Susan J. Schniepp


Susan J. Schniepp is a Pharmtech editorial advisory board (EAB) member

Susan J. Schniepp
Vice-President, OSO Biopharmaceuticals

Susan Schniepp has more than 28 years of experience in quality assurance for both the food and pharmaceutical industries. She has a degree in microbiology from Northern Illinois University and began her career in 1980 as a microbiologist in the food industry for Quaker Oats and M&M/Mars. In 1984, she began working for Searle Pharmaceuticals, and in 2000 she began working for Abbott Laboratories. In 2007, she formed her own consulting firm specializing in training, quality systems, technical writing, and standards interpretations. During her career in industry she had responsibilities for complaints, labeling, validation, documentation, and other quality systems, with a primary focus on establishing communications with compendial authorities.

Schniepp joined PDA in 2000 when she began working for Abbott Laboratories. She has presented at a number of PDA meetings and participated on a number of committees including the Joint Regulatory Conference Steering Committee, RAQC, Program Advisory Board, Technical Books Advisory Board, and The Membership Committee. In 2007, she was the recipient of PDA’s Distinguished Author Award for Understanding the United States Pharmacopeia and the National Formulary: Demystifying the Standards-Setting Process.

In addition to her PDA activities, Schniepp is chair of USP’s Monograph Development – Psychiatrics and Psychoactives Expert Committee for the 2005–2010 revision cycle, in addition to serving on the Council of Experts Executive Committee from 2005–2007. She is active in the Generic Pharmaceutical Association and founded both the Midwest and Western Compendial Discussion Groups.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here